Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Inhaled Velsecorat (AZD7594) via Nebulizer vs DPI
NCT04072562Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2019
- Primary completion
- Nov 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of velsecorat in asthma, sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration at 96 hours, Area under plasma concentration-time curve from zero to infinity at 96 hours and 1 more. Started Sep 2019; status: completed.
02
Drugs
velsecorat
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04072562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072562.